The medical and science communities quickly responded to the emergence of the SARS-CoV-2 virus early this year and the resulting COVID-19 pandemic. The sharing of information from the front lines soon transitioned to rapid reports and then to clinical trials that reported out in medical journals.

Importantly, throughout the year, ACC.org has served ACC members and the larger medical community through its coverage of the key, solid data, both positive and negative, that could affect clinical practice.

As we move into the winter phase of COVID-19, where already many more patients are being hospitalized, we share the top picks from ACC.org's Editor-in-Chief Kim A. Eagle, MD, MACC, and Senior Associate Editor Deepak L. Bhatt, MD, MPH, FACC, that show the evolution in our understanding of managing COVID-19 to guide practice.

Click the graphics below for a larger view.

Clinical Topics: Arrhythmias and Clinical EP, COVID-19 Hub, Dyslipidemia, Heart Failure and Cardiomyopathies, EP Basic Science, SCD/Ventricular Arrhythmias, Lipid Metabolism, Novel Agents, Statins

Keywords: ACC Publications, Cardiology Magazine, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Calcium Channels, Calcium Channel Blockers, Control Groups, Chloroquine, Coinfection, COVID-19, Critical Illness, Electronic Health Records, Cross-Sectional Studies, Hospital Mortality, Extracorporeal Membrane Oxygenation, Hydrocortisone, Glucocorticoids, Hydroxychloroquine, Length of Stay, Out-of-Hospital Cardiac Arrest, Oryza, Odds Ratio, Oxygen, Patient Discharge, Pandemics, Peptidyl-Dipeptidase A, Prevalence, remdesivir, Renin-Angiotensin System, Quarantine, Respiration, Artificial, Reverse Transcriptase Polymerase Chain Reaction, Respiratory Distress Syndrome, Retrospective Studies, severe acute respiratory syndrome coronavirus 2, severe acute respiratory syndrome coronavirus 2, Sodium Chloride Symporter Inhibitors, Troponin I, Waiting Lists

< Back to Listings